Poly morph isms of fibroblast growth factor receptor 4 have association with the development of prostate cancer and benign prostatic hyperplasia and the progression of prostate cancer in a Japanese population
Poly morph isms of fibroblast growth factor receptor 4 have association with the development of prostate cancer and benign prostatic hyperplasia and the progression of prostate cancer in a Japanese population
复制标题
DOI：
10.1002/ijc.23578
复制
发表时间：
2008-12-01
影响因子：
6.4
通讯作者：
Habuchi, Tomonori
中科院分区：
文献类型：
--
作者：
Ma, Zhiyong;Tsuchiya, Norihiko;Habuchi, Tomonori
成纤维细胞生长因子受体4（FGFR 4）是具有配体诱导的酪氨酸激酶活性的跨膜受体家族的成员。据报道，密码子388（Gly 388 Arg）处的甘氨酸（Gly）至精氨酸（Arg）多态性与某些癌症的风险增加相关，该多态性编码FGFR 4基因跨膜部分的氨基酸。我们研究了Gly 388 Arg多态性或FGFR 4内含子11（rs 2011017）的G或A多态性（位于Gly 388 Arg多态性的1，213个碱基对之外）与前列腺癌或良性前列腺增生（BPH）风险以及日本男性前列腺癌疾病状态之间的关联。对492例前列腺癌患者、165例BPH患者和179例男性对照进行了FGFR 4基因Gly 388 Arg和rs 2011077多态性的基因型检测。关于Gly 388 Arg多态性。与GlyGly基因型个体相比，ArgArg基因型个体患前列腺癌和BPH的风险增加2.207倍和1.958倍，患转移性前列腺癌的风险增加1.804倍。关于rs 2011077多态性，GG基因型个体患前列腺癌和BPH的风险是AA基因型个体的6.260倍和3.633倍，患转移性前列腺癌的风险是AA基因型个体的5.550倍。我们的研究结果表明，在日本人群中，Gly 388 Arg多态性的FGFR 4 Arg等位基因和rs 2011077多态性的G等位基因对前列腺癌和BPH的发展以及前列腺癌的进展具有显著影响。(C)2008 Wiley-Liss，Inc.
Fibroblast growth factor receptor 4 (FGFR4) is a member of a family of transmembrane receptors with ligand-induced tyrosine kinase activity. The Glycine (Gly) to Arginine (Arg) polymorphism at codon 388 (Gly388Arg), which encodes an amino acid in the transmembrane part of the FGFR4 gene, was reported to be associated with an increased risk in some carcinomas. We investigated the association between the Gly388Arg polymorphism or the G or A polymorphism at intron 11 (rs2011017) of FGFR4, which was located 1,213 base pairs apart from the Gly388Arg polymorphism, and the risk of prostate cancer or benign prostate hyperplasia (BPH), and the prostate cancer disease status in Japanese men. Genotypes of Gly388Arg and rs2011077 polymorphisms of FGFR4 were determined in 492 patients with prostate cancer, 165 patients with BPH and 179 male controls. Regarding the Gly388Arg polymorphism. individuals with the ArgArg genotype hail a 2.207- and 1.958-fold increased risk of prostate cancer and BPH, and a 1.804-fold increased risk of metastatic prostate cancer compared with those with the GlyGly genotype. Regarding the rs2011077 polymorphism, individuals With the GG genotype had a 6.260- and 3.633-fold increased risk of prostate cancer and BPH, and a 5.550-fold increased risk of metastatic prostate cancer compared with those with the AA genotype. Our results indicate that the FGFR4 Arg allele of the Gly388Arg polymorphism and the G allele of the rs2011077 polymorphism have a significant impact I the development of prostate cancer and BPH, and the progression of prostate of prostate cancer in a Japanese population. (C) 2008 Wiley-Liss, Inc.